Regenxbio
RGNX
7.60
+0.15
+1.95%
Regenxbio
US · RGNX
#3748 by market cap
Listed 2015
7.60
+0.15
+1.95%
Live - 5344 symbols - heartbeat 306s ago
· 2026-10-08 07:07
Pre-market
7.50
-1.25%
After-hours
7.61
+0.21%
Overnight
7.86
+3.49%
- Market cap
- 501.37M
- P/E (TTM)i
- -2.01
- P/Bi
- 6.99
- EPSi
- -3.76
- Div yieldi
- 0.00%
- 52W posi
- 20%
Reader sentiment
Are you bullish or bearish on RGNX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -2.99, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +104.54% YoY
Margins
- Gross margin
- 88.09%
- Operating margin
- -94.58%
- Net margin
- -113.75%
Key ratios & quality
- Altman Z-Scorei
- -2.99
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 218.51M | 35.23M | 154.57M | 470.35M | 112.72M | 90.24M | 83.33M | 170.44M |
| Gross profit | 208.87M | 26.99M | 118.85M | 418.51M | 58.18M | 53.03M | 49.76M | 150.14M |
| Selling & admin expenses | 36.85M | 51.82M | 63.82M | 79.33M | 85.28M | 88.49M | 76.62M | 82.86M |
| Research & development | 83.87M | 124.19M | 166.29M | 181.44M | 242.45M | 232.27M | 208.52M | 228.30M |
| Operating profit | 88.10M | -149.00M | -119.23M | 159.98M | -262.88M | -268.13M | -231.25M | -161.20M |
| Pretax profit | 104.12M | -97.49M | -106.01M | 141.25M | -280.41M | -263.65M | -227.10M | -193.88M |
| Tax | 4.18M | -2.76M | 5.24M | 13.41M | -84.00K | -152.00K | -- | -- |
| Net profit | 99.94M | -94.73M | -111.25M | 127.84M | -280.32M | -263.49M | -227.10M | -193.88M |
| Basic EPS | 3 | -3 | -3 | 3 | -7 | -6 | -5 | -4 |
| Diluted EPS | 2.73 | -2.58 | -2.98 | 2.91 | -6.50 | -6.02 | -4.59 | -3.76 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 89.01M | 21.36M | 29.73M | 30.34M | 6.39M | 108.02M |
| Gross profit | 85.58M | 16.15M | 24.01M | 24.41M | -4.68M | 106.98M |
| Selling & admin expenses | 20.35M | 19.88M | 20.25M | 22.38M | 21.31M | 21.62M |
| Research & development | 53.09M | 59.50M | 56.10M | 59.61M | 57.34M | 56.09M |
| Operating profit | 12.13M | -63.28M | -52.41M | -57.64M | -83.36M | 29.26M |
| Pretax profit | 6.08M | -70.87M | -61.94M | -67.15M | -90.05M | 22.71M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | 6.08M | -70.87M | -61.94M | -67.15M | -90.05M | 22.71M |
| Basic EPS | 0 | -1 | -1 | -1 | -2 | 0 |
| Diluted EPS | 0.12 | -1.38 | -1.20 | -1.30 | -1.72 | 0.43 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 337.91M | 345.03M | 531.20M | 518.83M | 415.98M | 334.97M | 278.00M | 281.28M |
| Cash & ST investments | 319.76M | 296.21M | 475.74M | 457.44M | 364.64M | 275.26M | 234.69M | 230.07M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 543.81M | 497.91M | 708.16M | 1.11B | 833.27M | 573.97M | 465.99M | 453.03M |
| Total current liabilities | 22.18M | 33.68M | 81.45M | 130.47M | 130.43M | 130.27M | 103.19M | 118.10M |
| Short-term debt | -- | 2.42M | 2.50M | 1.75M | 6.00M | 7.07M | 7.90M | 8.29M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 34,966,000.00 | 47,711,000.00 | 330,411,000.00 | 349,606,000.00 | 317,073,000.00 | 262,228,000.00 | 206,338,000.00 | 350,299,000.00 |
| Total equity | 508.85M | 450.20M | 377.75M | 764.30M | 516.20M | 311.74M | 259.65M | 102.73M |
| Retained earnings | -83.02M | -177.82M | -289.07M | -161.23M | -441.55M | -705.05M | -932.15M | -1.13B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 313.24M | 373.75M | 331.97M | 281.28M | 186.52M | 236.16M |
| Cash & ST investments | 267.87M | 323.30M | 274.21M | 230.07M | 150.49M | 105.52M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 490.93M | 581.03M | 525.20M | 453.03M | 341.89M | 386.62M |
| Total current liabilities | 106.73M | 119.54M | 124.57M | 118.10M | 71.11M | 82.62M |
| Short-term debt | 7.94M | 8.05M | 9.07M | 8.29M | 7.87M | 7.36M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 216,732,000.00 | 367,348,000.00 | 363,751,000.00 | 350,299,000.00 | 320,812,000.00 | 314,853,000.00 |
| Total equity | 274.20M | 213.68M | 161.45M | 102.73M | 21.08M | 71.77M |
| Retained earnings | -926.07M | -996.94M | -1.06B | -1.13B | -1.22B | -1.19B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 104.65M | -107.71M | -54.06M | 218.88M | -207.49M | -218.41M | -173.13M | -123.96M |
| Depreciation & amortization | 3.98M | 7.15M | 8.41M | 9.56M | 12.91M | 17.32M | 16.22M | 15.62M |
| Free cash flow | 91.37M | -119.43M | -80.93M | 134.70M | -238.21M | -228.37M | -175.56M | -126.38M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 190.56M | 1.31M | 1.80M | 218.21M | 1.74M | 6.70M | 132.26M | 1.05M |
| Ending cash balance | 76.61M | 70.84M | 339.76M | 347.24M | 98.98M | 36.55M | 59.56M | 36.50M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 33.63M | -49.34M | -55.96M | -52.29M | -76.19M | -62.24M |
| Depreciation & amortization | 3.96M | 3.91M | 3.89M | 3.87M | 3.86M | 3.76M |
| Free cash flow | 32.61M | -49.73M | -56.45M | -52.80M | -77.42M | -63.00M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 307.00K | 0 | 741.00K | 0 | 648.00K | 19.50M |
| Ending cash balance | 132.13M | 81.59M | 60.83M | 36.50M | 17.26M | 38.52M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 28.89 | -19.76 | -26.87 | 22.39 | -43.78 | -63.65 | -79.49 | -107.00 |
| ROA %i | 26.92 | -18.19 | -18.45 | 14.03 | -28.79 | -37.45 | -43.68 | -42.19 |
| ROIC %i | 25.97 | -19.95 | -24.96 | 23.20 | -35.21 | -50.72 | -57.79 | -57.52 |
| 5-year avg ROE %i | -- | -18.11 | -18.69 | -7.56 | -7.83 | -26.34 | -38.28 | -54.31 |
| EBIT margin %i | 40.32 | -422.89 | -68.09 | 35.62 | -228.12 | -284.55 | -257.35 | -87.34 |
| FCF / sales %i | 41.82 | -- | -- | 28.64 | -- | -- | -- | -- |
| Current ratioi | 15.24 | 10.25 | 6.52 | 3.98 | 3.19 | 2.57 | 2.69 | 2.38 |
| Quick ratioi | 14.81 | 9.93 | 6.37 | 3.75 | 3.03 | 2.32 | 2.48 | 2.18 |
| Debt / assetsi | 1.08 | 2.27 | 10.26 | 7.78 | 11.38 | 15.56 | 17.60 | 16.22 |
| LT debt / equityi | 1.15 | 1.97 | 18.57 | 11.11 | 17.20 | 26.38 | 28.55 | 63.48 |
| Interest coveragei | -- | -- | -136.50 | 6.38 | -11.06 | -37.42 | -16.94 | -3.31 |
| Revenue CAGR (3Y) %i | 206.51 | 97.28 | 145.92 | 29.12 | 47.35 | -16.42 | -43.84 | 14.78 |
| Net income CAGR (3Y) %i | -- | -- | -- | 8.55 | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | 13.81 | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -47.44 | -62.49 | -76.88 | -107.00 | -196.43 | -137.63 |
| ROA %i | -28.16 | -30.52 | -34.07 | -42.19 | -69.65 | -40.60 |
| ROIC %i | -33.32 | -40.25 | -43.60 | -57.52 | -109.79 | -71.54 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -88.33 | -93.57 | -84.16 | -87.34 | -278.82 | -88.54 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 2.93 | 3.13 | 2.66 | 2.38 | 2.62 | 2.86 |
| Quick ratioi | 2.69 | 2.88 | 2.41 | 2.18 | 2.27 | 2.57 |
| Debt / assetsi | 16.26 | 13.37 | 14.57 | 16.22 | 20.79 | 17.83 |
| LT debt / equityi | 26.22 | 32.59 | 41.77 | 63.48 | 299.78 | 85.83 |
| Interest coveragei | -7.19 | -4.89 | -3.22 | -3.31 | -5.42 | -3.68 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Development and commercialization of gene therapies to treat an array of diseases100.00%
Quote time 2026-10-08 07:07:57 · For reference only, not investment advice and not tailored to your situation.